Premium
Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors
Author(s) -
Peng Weidan,
Anderson Daniel G.,
Bao Yunhua,
Padera Robert F.,
Langer Robert,
Sawicki Janet A.
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20576
Subject(s) - prostate cancer , prostate , medicine , hyperplasia , cancer research , apoptosis , pathology , cancer , chemistry , biochemistry
BACKGROUND Currently available treatments for benign prostatic hyperplasia (BPH) and localized prostate cancer are generally effective but are often attended by serious side effects that impact on the quality of life. In particular, most current therapies are non‐specific, with surgery, radiation, and chemical ablation having the potential to cause damage to surrounding tissue. Here, we demonstrate the effectiveness of a prostate‐specific, locally delivered gene therapy for the targeted killing of prostate cells. METHODS Using a degradable, poly(β‐amino ester) polymer, poly(butane diol diacrylate co amino pentanol) (C32), we developed a nanoparticulate system to deliver a diphtheria toxin suicide gene (DT‐A) driven by a prostate specific promoter to cells. These C32/DT‐A nanoparticles were directly injected to the normal prostate and to prostate tumors in mice. RESULTS Nearly 50% of normal prostates showed a significant reduction in size, attributable to cellular apoptosis, whereas injection with naked DT‐A‐encoding DNA had little effect. Significant apoptosis was also observed in C32/DT‐A injected prostate tumors. Importantly, no damage to surrounding tissue was observed. CONCLUSIONS These results suggest that local delivery of poly(β‐amino ester) polymer/ DT‐A nanoparticles may have application in the treatment of BPH and prostate cancer. Prostate 67: 855–862, 2007. © 2007 Wiley‐Liss, Inc.